
News|Articles|September 27, 2023
What We are Reading: A Pioneer in GLP-1 Research Fights for Recognition
Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.
Advertisement
Svetlana Mojsov, Ph.D., is a researcher who, early in her career, was influential part of the team of researchers at Massachusetts General Hospital who discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss. Their work and the
Advertisement
Related to this article

Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.

Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide, citing a lack of assurance of sterility.

New data from Sutter Health suggest the real gap in GLP-1 access is physician awareness, not insurance coverage — and fixing it closed outcome disparities across every racial and ethnic group.

During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.

Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.

Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.

American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Algia Pharma completes investigational drug toxicology study for non-opioid acute pain regimen AlgiaPak
4
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
5

